USA Today, America’s top newspaper ranked by circulation, says claims circulating on social media that the Biden administration raised insulin prices by freezing a 340B-related Trump administration rule are “missing context.”
Last Friday, the national newspaper’s Fact Check feature delved into the online debate, which flared up after the new administration’s Jan. 21 decision to push back, from Jan. 22 until March 22, the effective date of the Trump administration’s rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price centers pay for those drugs under the 340B program. The rule implements an executive order Trump signed in July.
USA Today, America’s top newspaper ranked by circulation, says claims circulating on social media that the Biden administration raised insulin prices by freezing a 340B-related Trump administration rule are “missing context.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
